Download MendeleyDiscovery of a selective alpha-kinase 1 inhibitor for the rare genetic disease ROSAH syndrome.
Fan, J., Liu, D., Ming, Z., Yan, C., Dang, H., Pan, Y., Wei, X., Zhao, Z., Wang, W., Zhang, S., Chen, L., Cai, S., Ke, J., Luo, Y., Rao, L., Chen, J., Chen, Z., Zhou, J., Chen, F., Duan, X., Ren, B., Li, T.R., Melvin, L., Yogaratnam, J., Mahajan, V.B., Song, H., Lichenstein, H., Xu, T., Xu, C.(2025) Nat Commun 16: 8251-8251
- PubMed: 40925900 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41467-025-63731-5
- Primary Citation Related Structures:
9J4P - PubMed Abstract:
ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache) syndrome is a rare genetic disease caused by variants in alpha-kinase 1 (ALPK1) resulting in downstream pro-inflammatory signaling mediated by the TIFA/TRAF6/NF-κB pathway. Here, we report the design of an ALPK1 inhibitor, DF-003, with pharmacokinetic properties suitable for daily oral dosing. In biochemical assays, DF-003 potently inhibits human ALPK1 (IC 50 = 1.5 nM) and the ROSAH disease-causing mutant ALPK1[T237M] (IC 50 = 16 nM). When tested against a panel of 394 human kinases, DF-003 exhibits ≥860-fold selectivity over the closest kinase. In cell-based assays, DF-003 suppresses inflammatory cytokine signaling mediated both by wild-type ALPK1 and the disease-causing ALPK1[T237M] mutant. Using mice heterozygous for wild-type human ALPK1 and ALPK1 T237M established to model ROSAH syndrome that exhibit retinal microglial infiltration, astrocyte activation, and inflammatory cytokine upregulation in the retina, optic nerve, and cortex, we show that orally administered DF-003 is sufficient to inhibit these inflammatory phenotypes.
- Shanghai Yao Yuan Biotechnology Ltd (Drug Farm), Shanghai, China.
Organizational Affiliation:
